Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 29, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-10-29

Reporting Person: Cormorant Asset Management, LP (10% Owner)
Reporting Person: Chen Bihua (Director, 10% Owner)
Reporting Person: CORMORANT PRIVATE HEALTHCARE FUND I, LP (10% Owner)
Reporting Person: Cormorant Private Healthcare Fund II, LP (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (1000000)		Indirect
Series B Convertible Preferred Stock	$		Common Stock (1650165)		Indirect
Series C Convertible Preferred Stock	$		Common Stock (2631580)		Indirect
Series D Convertible Preferred Stock	$		Common Stock (712250)		Indirect
Series D-1 Convertible Preferred Stock	$		Common Stock (417360)		Indirect

Footnotes

F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock are convertible at any time at the holder's election, without payment of additional consideration. Such shares have no expiration date but are expected to convert into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP ("Fund II") and a managed account (the "Account"). Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP, LLC ("GP I") and Cormorant Private Healthcare GP II, LLC ("GP II") serve as General Partner of the Master Fund, Fund I and Fund II, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP I and GP II. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: Shares of Series A Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 842,500 shares held by the Master Fund and (ii) 157,500 shares held by the Account.

F4: Shares of Series B Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 396,040 shares held by the Master Fund, (ii) 1,155,115 shares held by Fund I, and (iii) 99,010 shares held by the Account.

F5: Shares of Series C Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 587,632 shares held by the Master Fund, (ii) 1,951,053 shares held by Fund I, and (iii) 92,895 shares held by the Account.

F6: Shares of Series D Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 136,823 shares held by the Master Fund and (ii) 575,427 shares held by Fund II.

F7: Shares of Series D-1 Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 80,175 shares held by the Master Fund and (ii) 337,185 shares held by Fund II.